traitement de la rest nose intra stent au ballon actif peeper n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Traitement de la resténose intra-stent au ballon actif Peeper PowerPoint Presentation
Download Presentation
Traitement de la resténose intra-stent au ballon actif Peeper

Loading in 2 Seconds...

play fullscreen
1 / 6

Traitement de la resténose intra-stent au ballon actif Peeper - PowerPoint PPT Presentation


  • 297 Views
  • Uploaded on

Traitement de la resténose intra-stent au ballon actif Peeper. 6- and 12-Month Clinical Results. Etude comparative ballon actif. PEPCAD II, comparative, randomisée ballon actif SeQuent Please versus actif Taxus liberté : Résultat à 3 ans.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Traitement de la resténose intra-stent au ballon actif Peeper' - viho


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
etude comparative ballon actif
Etude comparative ballon actif

PEPCAD II, comparative, randomisée ballon actif SeQuent Please versus actif Taxus liberté : Résultat à 3 ans

Comparé au stent actif à libération de paclitaxel, SeQuent Please présente des résultats angiographique et clinique plus favorable à 6 mois et 3 ans de suivi.

slide4
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
  • Martin Unverdorben, MD; Christian Vallbracht, MD; Bodo Cremers, MD; HubertusHeuer, MD; Christian Hengstenberg, MD; Christian Maikowski, MD; Gerald S. Werner, MD; Diethmar Antoni, MD; Franz X. Kleber, MD; Wolfgang Bocksch, MD; Matthias Leschke, MD; Hanns Ackermann, PhD; Michael Boxberger, PhD Ulrich Speck, PhD; Ralf Degenhardt, PhD; Bruno Scheller, MD.
slide5

Paclitaxel-eluting Balloon Catheter Versus Repeat Sirolimus-elutingStent for The Treatment of Sirolimus-eluting Stent Restenosis

    • Seiji Habra, Kazushige Kadota, Naoki Saito, Suguru Otsuru, Daiji Hasegawa, Yoshikazu Shigemoto, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Naoki Oka, Tsuyoshi Goto, Kazuaki Mitsudo
    • Kurashiki central hospital, Kurashiki-shi, Japan
  • Methods : From June 2004 to december 2010, 221 consecutive patients with 245 lesions after revascularization for SES restenosis were enrolled. Follow-up angiogram was obtained 6 to 8 month after procedure. All of the initial SES were implanted in de novo lesions. We compared characteristics of patients and lesions between the two groups (PEB for SES restenosis: PEB groupe, n=131, repeat SES implatation for SES restenosis : SES group, n=114)
  • Results : No significant differences were observed in clinical characteristics between the two groups. Reference diameter (RD) and minimal lumen diameter (MLD) were similar between the two groups (RD : 2.83 ± 0.42mm vs 2.91 ± 0.48, p=0.2, MLD : 0.85 ± 0.51mm vs 0.91 ± 0.52mm, p=0.4). Lesion lenght was longer in the DEB group (15.5 ± 9.0mm vs 13.3 ± 6.9, p=0.033). Acute gain was larger in the SES group (1.20 ± 0.62mm vs 1.71 ± 0.63mm, p<0.0001). Follow-up rate was 91% (223/245 lesions). The incidence of recurrent restenosis was 19.1% in the DEB group and 24.1% in the SES group (p=0.4). DEB group led to a significant reduction in 6-8 month late lumen loss (0.27 ± 0.68mm vs 0.63 ± 0.74mm, p=0.0002) and in target lesion revascularization (13.0% vs 23.2%, p=0.049) compared to SES group.
  • Conclusion : In patients with SES restenosis, PEB provided much better angiographic outcomes than repeat SES implantation.
slide6

Dans notre centre

    • Accès précoce au ballon actif
    • Réalisation de nombreux cas de resténose augmentés par Delux
  • Toutes les resténosessont traitées au ballon actif:
    • Très peu de nouveau Stent
    • Très peu de retours
  • Ballon coaté au Sirolimus…